Modafinil: A Review of Neurochemical Actions and Effects on Cognition
The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term 'modafinil' and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including workin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, side effects of alpha agonists like guanfacine and clonidine include high prevalence of somnolence or sedating effects,168,169”
From Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome (2023) · cites this paper as [168]
In the citing paper
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472 · cited 7×
“Importantly, modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described in the Aston…”
BackgroundMethodResultInfluentialNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“m Fos in orexin neurons in perfornical area 150 mg/kg i.p. Immunohisto-chemistry Mice Chemelli et al, 1999 75 mg/kg i.p. Immunohisto-chemistry Rat Scammell et al, 2000 No binding to orexin-1 receptor IC50 410mM 125I-human-orexin B displacement Transfected Chinese Hamster Ovary cells Wieland et al,…”
BackgroundAston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“It appears also that when levels of tonic LC activity are minimal, such as during sleep, grooming, and eating, that phasic responses are also less robust (Aston-Jones and Bloom, 1981).”
BackgroundTask-evoked pupillary responses, processing load, and the structure of processing resources.
Beatty, J. (1982) · Psychological Bulletin · doi:10.1037/0033-2909.91.2.276 · Cited by 1,959 · cited 1×
“…modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described…”
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 15×
“Inhibition of DA cell firing in VTA/SN; blocked by Sulpiride 10mM but not by Prazosin 20 mM Extracellular recording Rat brain slice Korotkova et al, 2006 Hyperpolarization of VTA neurons, blocked by Sulpiride 10mM 20–50mM Whole-cell patch clamp Isolated VTA neurons No effect on mesencephalic DA neuron activity 128 mg/…”
BackgroundInfluentialDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929 · cited 5×
“Thalamic NET occupancy: 16, 44% 5, 8 mg/kg i.v. PET with [11C]MeNER Rhesus monkey Madras et al, 2006 NET binding IC50¼ 35.6mM [3H] NE Human Embryo Kidney No effect on pontine NE neuron activity 128 mg/kg i.p. Single-unit recording Rat (anesthetized) Akaoka et al, 1991 Extracellular NE: m in PFC, medial hypothalamus 12…”
BackgroundInfluentialDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769 · cited 7×
“…extracellular DA levels (measured by microdialysis) that are increased significantly in the rat prefrontal cortex (PFC) (de Saint Hilaire et al, 2001), and in the caudate nucleus of narcoleptic dogs (Wisor et al, 2001), although only minimally in the rat hypothalamus (de Saint Hilaire et al, 2001).”
BackgroundInfluentialThe role of locus coeruleus in the regulation of cognitive performance
Usher, M., Cohen, J. D., Servan-Schreiber, D., Rajkowski, J., & Aston-Jones, G. (1999) · Science · doi:10.1126/science.283.5401.549 · Cited by 715
Research works printed but not linked: 1
- Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC et al (1999b). A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39: 30–40. · DOI · Paper page
Cited by
Items 301–400 of 735
Ray, K., Chatterjee, A., Panjwani, U., Kumar, S., Sahu, S., Ghosh, S., Thakur, L., & Anand, J. P. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.06.012 · Cited by 26
Dejban, P., Rahimi, N., Takzare, N., & Dehpour, A. R. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00054-5 · Cited by 24
Varanese, S., Perfetti, B., Gilbert, R., Thomas, A., ONOFRJ, M. C., & Rocco, A. D. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3952 · Cited by 23
Noradrenergic Enhancement of Motor Learning, Attention, and Working Memory in Humans
Kuo, H.-I., Qi, F., Paulus, W., Kuo, M., & Nitsche, M. A. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab006 · Cited by 25
Garrison, M. K., Yates, C. C., Reese, N. B., Skinner, R. D., & García‐Rill, E. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.09.019 · Cited by 25
“A second possible mechanism of action of modafinil on the SR and FDD is through modulation of monoamine transporters and receptors (see Minzenberg and Carter, 2008 for a review).”
Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens
Funayama, T., Ikeda, Y., Tateno, A., Takahashi, H., Okubo, Y., Fukayama, H., & Suzuki, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3499-0 · Cited by 25
“Pharmacological effects of modafinil on cognitive functions have been examined in humans (Minzenberg and Carter 2008), although there is conflicting literature on these effects (Lynch et al. 2011).”
BackgroundInfluentialModafinil as a cognitive enhancer of spatial working memory in rats
Murphy, H. M., Ekstrand, D., Tarchick, M. J., & Wideman, C. H. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.02.003 · Cited by 23
The impact of sleep deprivation on surgeons' performance during night shifts.
Amirian, I. (2014) · PubMed · Cited by 33
Agitation and Psychosis Associated With Dementia With Lewy Bodies Exacerbated by Modafinil Use
Prado, E., Paholpak, P., Ngo, M., Porter, V. R., Apostolova, L. G., Marrocos, R. P., & Ringman, J. M. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512456450 · Cited by 23
A Data Mining Approach to In Vivo Classification of Psychopharmacological Drugs
Kafkafi, N., Yekutieli, D., & Elmer, G. I. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.103 · Cited by 22
“Modafinil, considered a psychomotor stimulant that inhibits dopamine and norepinephrine uptake (Minzenberg and Carter, 2008), was not as fully ‘efficacious’ in its effect on our psychomotor predictor as the more typical psychomotor stimulants, and also had a very slight but still significant effect on the opioid predi…”
BackgroundWittkampf, L. C., Arends, J., Timmerman, L., & Lancel, M. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312441815 · Cited by 23
“As modafinil lacks many of the behavioural and neurochemical effects of amphetamine [Minzenberg and Carter, 2008], it may therefore not evoke or enhance positive symptoms.”
BackgroundNew Approaches for the Treatment of Sleep Disorders
DeMartinis, N. A., Kamath, J., & Winokur, A. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57005-0 · Cited by 26
Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination
Vodovar, D., Duchêne, A., Wimberley, C., Leroy, C., Pottier, G., Dauvilliers, Y. A., Giaume, C., Lin, J., Mouthon, F., Tournier, N., et al. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy027 · Cited by 23
“Data presented in this study point toward a putative role of THN102 on those dopaminergic and glutamatergic neurotransmission systems, potential targets of modafinil (Minzenberg and Carter, 2008).”
BackgroundInfluentialEffect of modafinil on learning performance and neocortical long-term potentiation in rats
Burgos, H., Castillo, A., Flores, O., Puentes, G. C., Morgan, C., Gatica, A., Cofré, C., Hernández, A., Laurido, C., & Constandil, L. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.08.010 · Cited by 22
“So, it is plausible that chronicmodafinil had affected operant conditioning learning by altering the normal function of the prefrontal cortex, as this drug has been reported to modify dopaminergic, noradrenergic orGABAergicmechanisms in theneocortex [14].”
BackgroundMethylphenidate does not affect convergent and divergent creative processes in healthy adults
Baas, M., Boot, N. C., van Gaal, S., Dreu, C. K. W. D., & Cools, R. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116279 · Cited by 22
Differential effects of modafinil, methamphetamine, and MDMA on agonistic behavior in male mice
Máchalová, A., Šlais, K., Vršková, D., & Šulcová, A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.04.013 · Cited by 26
Modafinil Effects on Behavior and Oxidative Damage Parameters in Brain of Wistar Rats
Ornell, F. R., Valvassori, S. S., Steckert, A. V., Deroza, P. F., Resende, W. R., Varela, R. B., & Quevedo, J. (2014) · Behavioural Neurology · doi:10.1155/2014/917246 · Cited by 23
“It is known that the amygdala is rich in catecholaminergic and serotoninergic projections [42], and then probably MD reduces amygdala reactivity by changes in intra-amygdala signaling resulting from alterations in noradrenaline, dopamine, serotonin, or GABA systems [1, 43, 44] or from a combination of these effects.”
BackgroundSmart, K. A., Desmond, R. C., Poulos, C. X., & Zack, M. H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.015 · Cited by 23
“However, modafinil also increases transmission of norepinephrine, glutamate, orexin, histamine and to a lesser extent, serotonin (Minzenberg and Carter, 2008).”
BackgroundEffects of Psychostimulants on Alertness and Spatial Bias in Healthy Participants
Dodds, C., Müller, U., & Manly, T. (2009) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2009.21046 · Cited by 24
Early markers of cognitive enhancement: developing an implicit measure of cognitive performance
Pringle, A., Browning, M. D., Parsons, E., Cowen, P. J., & Harmer, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3186-6 · Cited by 26
van Amelsvoort, T., & Hernaus, D. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00082 · Cited by 22
“, modafinil (34) and atomoxetine (35)], and noradrenergic [e.”
Perkins, F. N., & Freeman, K. B. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.06.015 · Cited by 21
“It has been shown to have weak effects at catecholamine transporters where it causes modest extracellular increases in these neurotransmitters (Minzenberg and Carter, 2008).”
BackgroundPhilipsen, M. H., Ranjbari, E., Gu, C., & Ewing, A. G. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202105004 · Cited by 22
Short- and long-term treatment with modafinil differentially affects adult hippocampal neurogenesis
Brandt, M., Ellwardt, E., & Storch, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.08.014 · Cited by 24
“Mdf also increases brain levels of serotonin, glutamate and histamine, but decreases GABA levels (for overview see, (Minzenberg and Carter, 2008)).”
Vivanco, P., Studholme, K. M., & Morin, L. P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.09.025 · Cited by 23
“MOD appears to influence general activity primarily via the DA R1 receptor, but also modifies locomotor activity through multiple systems in mice and rats (Minzenberg and Carter, 2008, Young et al., 2011).”
BackgroundSpencer, T. J., Madras, B. K., Bonab, A. A., Dougherty, D. D., Clarke, A., Mirto, T., Martin, J., & Fischman, A. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.026 · Cited by 22
The Future of Steroids for Performance Enhancement in the U.S. Military
Peltier, C., & Pettijohn, K. A. (2018) · Military Medicine · doi:10.1093/milmed/usy093 · Cited by 22
Modafinil, an atypical CNS stimulant?
Hersey, M., & Tanda, G. (2023) · Advances in pharmacology · doi:10.1016/bs.apha.2023.10.006 · Cited by 23
Ultra short manic-like episodes after antidepressant augmentation with modafinil
Fountoulakis, K. Ν., Siamouli, M., Panagiotidis, P., Magiria, S., Kantartzis, S., Iacovides, A., & Kaprinis, G. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.006 · Cited by 20
Federici, M., Latagliata, E. C., Rizzo, F. R., Ledonne, A., Gu, H. H., Romigi, A., Nisticò, R., Puglisi‐Allegra, S., & Mercuri, N. B. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.071 · Cited by 22
“In addition, modafinil has been proposed to improve concentration (Minzenberg and Carter, 2008) and to lessen the symptoms of attention-deficit hyperactivity disorder (ADHD) (Turner et al.”
BackgroundThe increasing lifestyle use of modafinil by healthy people: safety and ethical issues
Mann, S. P., & Sahakian, B. J. (2015) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2015.05.004 · Cited by 21
Ahmed, A. O., & Bhat, I. (2014) · CNS Drugs · doi:10.1007/s40263-014-0146-6 · Cited by 23
Roerig, J. L., Steffen, K. J., Mitchell, J. E., Crosby, R. D., & Gosnell, B. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.037 · Cited by 21
Modafinil enhances alerting-related brain activity in attention networks
Ikeda, Y., Funayama, T., Tateno, A., Fukayama, H., Okubo, Y., & Suzuki, H. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4614-9 · Cited by 19
“The mechanism of action of modafinil is unique and complex (Mereu et al. 2013; Minzenberg and Carter 2008).”
BackgroundInfluentialLeeman, R. F., Bogart, D., Fucito, L. M., & Boettiger, C. A. (2014) · Current Addiction Reports · doi:10.1007/s40429-013-0008-1 · Cited by 20
Differential behavioral profiling of stimulant substances in the rat using the LABORAS™ system
Castagné, V., Wolinsky, T. D., Quinn, L. P., & Virley, D. J. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.001 · Cited by 19
Cognitive evoked potentials in narcolepsy: A review of the literature
Raggi, A., Plazzi, G., Pennisi, G., Tasca, D., & Ferri, R. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.12.001 · Cited by 19
Alam, N., & Choudhary, K. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0190-x · Cited by 20
“…the extracellular levels of Dopamine (DA) (Challman and Lipsky 2000; Volkow et al. 2009) and act as a cognitive enhancer and this aspect of the drug is continued to be explored in different age groups (Minzenberg and Carter 2008; Wesensten 2006; Ballon and Feifel 2006; Mignot et al. 1994).”
BackgroundMethodInfluentialYan, Y.-D., Chen, Y., Wang, C.-Y., Ye, C.-B., Hu, Z., Behnisch, T., Huang, Z., & Yang, S.-R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01229-6 · Cited by 19
Mistarz, N. T., Andersen, K., Nielsen, A. S., Goudriaan, A. E., Michel, T. M., Skøt, L., Nielsen, D. G., & Mellentin, A. I. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.038 · Cited by 19
Mesencephalic dopamine neurons are essential for modafinil‐induced arousal
Yang, Y., Dong, H., Shen, Y., Li, L., Lazarus, M., Qu, W., & Huang, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15660 · Cited by 19
“…that modafinil can increase catecholamine, 5-hydroxytryptamine (5-HT; serotonin) and glutamate release and decrease gamma-aminobutyric acid (GABA) release, in various brain regions (Minzenberg & Carter, 2008), whereas there is no evidence that has elucidated specific brain targets for modafinil.”
BackgroundKrief, S., Berrebi‐Bertrand, I., Nagmar, I., Giret, M., Belliard, S., Perrin, D., Uguen, M., Robert, P., Lecomte, J., Schwartz, J.-C., et al. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.855 · Cited by 20
Żółkowska, D., Andres‐Mach, M., Prisinzano, T. E., Baumann, M. H., & Łuszczki, J. J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3884-3 · Cited by 19
“Despite the widespread clinical use of modafinil, the precise mechanisms underlying its therapeutic efficacy are complex and not well understood (for review, see Ballon and Feifel 2006; Minzenberg and Carter 2008).”
BackgroundInfluentialJoos, L., Goudriaan, A. E., Schmaal, L., van den Brink, W., Sabbe, B. G., & Dom, G. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503505 · Cited by 19
“…attention in healthy individuals as well as in different patient populations, such as patients with attention deficit hyperactivity disorder (ADHD), major depressive disorder, schizophrenia and substance use disorders (for reviews see Joos et al., 2010; Minzenberg and Carter, 2008).”
BackgroundPharmacological Neuroenhancement: Substances and Epidemiology
Franke, A. G., & Lieb, K. (2013) · Trends in augmentation of human performance · doi:10.1007/978-94-007-6253-4_2 · Cited by 23
Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders
Walker, L. C., & Lawrence, A. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1502269 · Cited by 22
“well as the α1-adrenergic receptor, are important for mediating the effect of modafinil on cognition and arousal [21].”
BackgroundMöglichkeiten und Grenzen des pharmakologischen Neuroenhancements
Normann, C., Boldt, J., Maio, G., & Berger, T. (2009) · Der Nervenarzt · doi:10.1007/s00115-009-2858-2 · Cited by 24
Approaches to measuring the effects of wake‐promoting drugs: a focus on cognitive function
Edgar, C. J., Pace-Schott, E. F., & Wesnes, K. A. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1034 · Cited by 19
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
“It is hypothesized to exert its mechanism of action primarily through the histamine system, as well as indirectly enhancing dopamine and norepinephrine neurotransmission in the prefrontal cortex (Minzenberg and Carter, 2008).”
BackgroundMohamed, A. D., & Lewis, C. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110639 · Cited by 19
Li, J., Yang, X., Zhou, F., Liu, C., Wei, Z., Xin, F., Daumann, B., Daumann, J., Kendrick, K. M., & Becker, B. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0625-z · Cited by 20
“A previous study suggested that MOD-enhanced arousal and neural activity was attenuated by the β-adrenergic antagonist propranolol [22], which may together point to a β-adrenergic-mediated mechanism of MOD on amygdala activation during cognitive conflict.”
BackgroundInfluentialHayley, A. C., Shiferaw, B. A., & Downey, L. A. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101929 · Cited by 21
Examining Reports and Policies on Cognitive Enhancement: Approaches, Rationale, and Recommendations
Outram, S. M., & Racine, É. (2011) · Accountability in Research · doi:10.1080/08989621.2011.606734 · Cited by 20
“Studies have been carried out with respect to the cognitive enhancing effects of both methylphenidate and modifinil in nominally healthy individuals (Elliott et al., 1997; Koelega, 1993; Kumar, 2008; Mehta et al., 2000, Minzenberg and Carter, 2008; Randall et al., 2005; Turner et al., 2003).”
BackgroundDifferential effects of modafinil on memory in naïve and memory-impaired rats
Garcia, V. A., de Freitas, B. S., Busato, S. B., Portal, B. C. D., Piazza, F. C., & Schröder, N. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.038 · Cited by 18
Fernández, A., Mascayano, F., Castro, W. L., Painel, A., Norambuena, J., & Madrid, E. (2015) · Medwave · doi:10.5867/medwave.2015.05.6166 · Cited by 21
Wuo‐Silva, R., Fukushiro, D. F., Hollais, A. W., Santos-Baldaia, R., Mári-Kawamoto, E., Berro, L. F., Yokoyama, T. S., Lopes-Silva, L. B., Bizerra, C. S., Procópio‐Souza, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00420 · Cited by 18
“…and neurologic disorders, including attention-deficit/hyperactivity disorder, cognitive deficits related to schizophrenia and Alzheirmer’s disease, sleepiness and fatigue related to Parkinson’s disease and amyotrophic lateral sclerosis (Ballon and Feifel, 2006; Minzenberg and Carter, 2008).”
BackgroundSase, S., Khan, D., Sialana, F. J., Höger, H., Russo-Schlaff, N., & Lübec, G. (2012) · Amino Acids · doi:10.1007/s00726-012-1306-y · Cited by 19
Élie, D., Gagnon, P. R., Gagnon, B., & Giguere, A. M. C. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500608 · Cited by 17
Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease
Choi, S., Kim, J. A., Li, H., Jo, S.-E., Lee, H., Kim, T. H., Kim, M., Kim, S.-J., & Suh, S. H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112372 · Cited by 17
Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia
Minzenberg, M., Yoon, J. H., Cheng, Y., & Carter, C. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.271 · Cited by 18
Self-citationJoo, E. Y., Hong, S. B., Kim, H.-J., Lim, Y.-H., Koo, D.-L., Ji, K., & Tae, W. (2010) · Sleep Medicine · doi:10.1016/j.sleep.2010.07.003 · Cited by 17
“The awakening mechanisms involved have not been determined, but current speculations do not include an increase in hypocretinergic transmission [35,36].”
BackgroundSoeiro, A. D. C., Moreira, K. D. M., Abrahao, K. P., Quadros, I. M., & Oliveira, M. G. M. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.05.023 · Cited by 19
“treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea syndrome, and shift work sleep disorder [1].”
BackgroundMilella, M. S., Passarelli, F., Carolis, L. D., Schepisi, C., Nativio, P., Scaccianoce, S., & Nencini, P. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1909-5 · Cited by 18
Punzi, M., Gili, T., Petrosini, L., Caltagirone, C., Spalletta, G., & Sensi, S. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00085 · Cited by 17
“Modafinil can also increase extracellular brain levels of serotonin, glutamate, histamine, and orexin as well as decrease the release of gamma-amino-butyric acid (Minzenberg and Carter, 2008).”
BackgroundInfluentialThe potential protective effect of modafinil in intestinal ischemic reperfusion-induced in rats
Kamel, M. Y., Ahmed, S. M., & Abdelzaher, W. Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106983 · Cited by 18
Wiggs, K. K., Froehlich, T. E., & Becker, S. P. (2023) · CNS Drugs · doi:10.1007/s40263-023-00999-5 · Cited by 16
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
BackgroundDistinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
Loomis, S., McCarthy, A. P., Baxter, C., Kellett, D. O., Edgar, D. M., Tricklebank, M. D., & Gilmour, G. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3936-8 · Cited by 16
“This represents a potentially important disconnect to existing clinical data, whereby most human studies report positive effects of standard 10 or 20 mg amphetamine doses on attentional and other cognitive tasks following sleep deprivation (see review by Minzenberg and Carter 2008).”
BackgroundInfluentialGibuła‐Tarłowska, E., Korz, V., Łopatyńska-Mazurek, M., Chłopaś‐Konowałek, A., Grochecki, P., Kalaba, P., Dragačević, V., Kotlinski, R., Kujawski, R., Szulc, M., et al. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113326 · Cited by 16
Mutti, C., Brunetti, V., Figorilli, M., Liguori, C., Pizza, F., Proserpio, P., Sacco, T., Pedrazzi, G., Lecomte, I., Blanchard, N., et al. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06210-9 · Cited by 17
“Modafinil has several effects on catecholamine systems in the brain, resulting in increased levels of dopamine, norepinephrine, serotonin, and histamine; activation of the orexinergic system; and decreased GABA[37].”
BackgroundInfluentialModafinil Improves Autism-like Behavior in Rats by Reducing Neuroinflammation
Bağcıoğlu, E., Solmaz, V., Erbaş, O., Özkul, B., Çakar, B., Uyanıkgil, Y., & Söğüt, İ. (2023) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-023-10061-2 · Cited by 16
Hypoactive Delirium: Differential Diagnosis, Evaluation, and Treatment
Rosen, J. H., Bieber, E. D., Matta, S. E., Sayde, G. E., Fedotova, N. O., deVries, J., Rafferty, M., & Stern, T. A. (2024) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.23f03602 · Cited by 22
“45 This increase of neurotransmitters in the synaptic cleft facilitates neuronal communication and enhances overall brain function.”
Aher, Y. D., Subramaniyan, S., Shanmugasundaram, B., Sase, A., Saroja, S. R., Holy, M., Höger, H., Beryozkina, T., Sitte, H. H., Leban, J. J., et al. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00020 · Cited by 15
“…inhibition exerts its function in a complex way Frontiers in Behavioral Neuroscience | www.frontiersin.org 9 February 2016 | Volume 10 | Article 20 (Minzenberg and Carter, 2008; Qu et al., 2008; Spiller et al., 2013) and further behavioral, pharmacokinetic, neurotoxicity, and molecular studies in…”
BackgroundGolini, E., Rigamonti, M., Raspa, M., Scavizzi, F., Falcone, G., Gourdon, G., & Mandillo, S. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1130055 · Cited by 15
“It is thus considered as a primary hypersomnia in DM1 that is efficaciously treated with the psychostimulant modafinil, an effective and well-tolerated drug acting primarily on blocking catecholamines re-uptake as well as affecting serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the br…”
BackgroundPuech, C., Badran, M., Barrow, M. B., Runion, A. R., & Gozal, D. (2023) · SLEEP · doi:10.1093/sleep/zsad057 · Cited by 15
Dell'osso, B., Ketter, T., Cremaschi, L., Spagnolin, G., & Altamura, A. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0378-z · Cited by 21
“and influence orexinergic neurotransmission [20].”
Temperament and Character Correlates of Neuropsychological Performance
Cassimjee, N., & Murphy, R. (2010) · South African Journal of Psychology · doi:10.1177/008124631004000202 · Cited by 21
Impaired serial ordering in nondemented patients with mild Parkinson’s disease
Ma, J., Ma, S., Zou, H., Zhang, Y., Chan, P., & Ye, Z. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197489 · Cited by 16
Modafinil inhibits KCa3.1 currents and muscle contraction via a cAMP-dependent mechanism
Choi, S., Kim, M. Y., Joo, K. Y., Park, S., Kim, J. A., Jung, J., Oh, S., & Suh, S. H. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.02.009 · Cited by 15
Cognitive Remediation for Schizophrenia
Mogami, T., 2238, Mogami, T., 80368414, & 100000310 (2012) · PsycEXTRA Dataset · doi:10.1037/e675522012-001 · Cited by 15
Sun, H., MacLeod, C., Mostoller, K., Mahon, C., Han, L., Renger, J. J., Ma, J., Brown, K. R., Schulz, V., Kay, G. G., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.182 · Cited by 14
“Modafinil is thought to act through non‐histaminergic pathways.(10) MK‐0249 doses of 10–12mg, predicted to result in 85–90% occupancy of H3 receptors at peak plasma concentration, did not differ from placebo on maintenance of wakefulness test (MWT) sleep latency, a standard outcome The Journal of Clinical Pharmacology…”
BackgroundThe billion dollar business of being smart
Chinthapalli, K. (2015) · BMJ · doi:10.1136/bmj.h4829 · Cited by 14
Pliszka, A. G. (2022) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2022.170402 · Cited by 12
Allen, M. D., Hedges, D. W., Farrer, T. J., & Larson, M. J. (2011) · Neurocase · doi:10.1080/13554794.2010.547508 · Cited by 14
Chen, C., Yang, S.-R., Liu, Y., Qu, W., Urade, Y., & Huang, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076102 · Cited by 14
“It has been approved for use in the treatment of excessive daytime sleepiness [5,6] and has been shown to efficaciously improve cognitive performance and to boost learning in methamphetamine-dependent participants [5,7–9].”
BackgroundArmodafinil-induced wakefulness in animals with ventrolateral preoptic lesions
Fuller, P. M., Vetrivelan, R., & Saper, C. B. (2014) · Nature and Science of Sleep · doi:10.2147/nss.s53132 · Cited by 15
“Introduction Modafinil is a wake-promoting agent that is currently approved by the US Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea/ hypopnea syndrome.(1,2) As the wake-promoting effects are due ma…”
Quisenberry, A. J., Prisinzano, T. E., & Baker, L. E. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0031832 · Cited by 14
“Research exploring modafinil’s neuropharmacological actions has implicated several neurotransmitter systems, including orexin, serotonin, GABA, and dopamine (Dopheide, Morgan, Rodvelt, Schachtman, & Miller, 2007; Minzenberg & Carter, 2008; Wisor et al., 2001; Zolkowska et al., 2009).”
Effects of acute modafinil on cognition in trichotillomania
Chamberlain, S. R., Grant, J. E., Costa, A. C. L., Müller, U., & Sahakian, B. J. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1981-x · Cited by 16
Dias, V. T., Rosa, H. Z., D’avila, L. F., Vey, L. T., Barcelos, R. C. S., & Bürger, M. E. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.007 · Cited by 15
Raineri, M., González, B., Rivero‐Echeto, M. C., Muñiz, J. A., Gutiérrez, M. L., Ghanem, C. I., Cadet, J. L., García‐Rill, E., Urbano, F. J., & Bisagno, V. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9493-9 · Cited by 14
“2009) and low affinity for norepinephrine or 5-hydroxytryptamine transporters (NET and SERT) (Madras et al. 2006; Minzenberg and Carter 2008), positron emission tomography experiments in humans have revealed that therapeutic doses of modafinil occupy a substantial proportion of striatal DAT sites in human subjects and…”
Could Modafinil Prevent Psychostimulant Addiction? An Experimental Study in Rats
Dias, V. T., Vey, L. T., Rosa, H. Z., D’avila, L. F., Barcelos, R. C. S., & Bürger, M. E. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12821 · Cited by 15
Open-label placebo treatment does not enhance cognitive abilities in healthy volunteers
Hartmann, H., Forkmann, K., Schmidt, K., Kleine‐Borgmann, J., Albers, J., Wiech, K., & Bingel, U. (2023) · Scientific Reports · doi:10.1038/s41598-023-45979-3 · Cited by 13
Multisensory integration, brain plasticity and optogenetics in visual rehabilitation
Lucchesi, M., Maya‐Vetencourt, J. F., & Rusciano, D. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1590305 · Cited by 17
“Atomoxetine works by inhibiting the reuptake of norepinephrine, which helps improve attention and reduce impulsivity (81, 83, 84).”
Howard, R., Roth, T. G., & Drake, C. L. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000136 · Cited by 15
“The current study found that armodafinil significantly improved performance on measures of both free recall memory and attention, again consistent with previous armodafinil trials in SWD,(22) as well as simulated shift work.(21,38) Limitations of the study included the single dose utilized with a single administration…”
ResultEfficient atom and step economic (EASE) synthesis of the “smart drug” Modafinil
Maurya, S., Yadav, D., Pratap, K., & Kumar, A. (2016) · Green Chemistry · doi:10.1039/c6gc02623k · Cited by 13
Advances in the pharmacotherapeutic management of dementia with Lewy bodies
Palermo, G., Ceravolo, R., & Bonuccelli, U. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519548 · Cited by 13
“In recent years, interest has emerged about the possibility that wake-promoting agents, such as modafinil and armodafinil, may have advantageous effects for cognitive processes and psychomotor vigilance also in Lewy body disorders [92].”
BackgroundWuo‐Silva, R., Fukushiro-Lopes, D. F., Fialho, B. P., Hollais, A. W., Santos-Baldaia, R., Marinho, E. A. V., Mári-Kawamoto, E., Yokoyama, T. S., Lopes-Silva, L. B., Berro, L. F., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00211 · Cited by 14
“Modafinil (diphenyl-methyl sulphonyl-2-acetamide) is a wakepromoting drug with psychostimulant properties that has been approved for the treatment of excessive daytime sleepiness in narcolepsy, obstructive sleep apnea and shift workers sleep disorder (Minzenberg and Carter, 2008).”
BackgroundInfluentialMcCarthy, A. P., Svensson, K. A., Shanks, E., Brittain, C., Eastwood, B. J., Kielbasa, W., Biglan, K., & Wafford, K. A. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000719 · Cited by 12
Kanjwal, K., Saeed, B., Karabin, B., Kanjwal, Y., & Grubb, B. P. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181da0763 · Cited by 12
“The pharmacologic effects of modafinil are complex and it is thought to alter various neurotransmitters in the brain.(17) In animal studies, modafinil has been reported to decrease the levels of inhibitory neurotransmitters gamma amino butyric acid and increase the levels of glutamate and serotonin.”
BackgroundModafinil Dependence: A Case with Attention-Deficit/Hyperactivity Disorder
Alaçam, H., Başay, Ö., Tümkaya, S., Mart, M., & Kar, G. (2018) · Psychiatry Investigation · doi:10.30773/pi.2016.10.25 · Cited by 14
Yin, F., Zhang, J., Lu, Y., Zhang, Y., Liu, J., Deji, C., Qiao, X., Gao, K., Xu, M., Lai, J., et al. (2021) · Addiction Biology · doi:10.1111/adb.13103 · Cited by 13
Metadata
- Authors
- Minzenberg, M. J., & Carter, C. S.
- Affiliations
- University of California Davis Medical Center (US)
- Corresponding author
- Minzenberg, Michael J
- Venue
- Neuropsychopharmacology
- Published
- 2007-08-22
- Volume
- 33
- Issue
- 7
- Pages
- 1477-1502
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2122011624
- Semantic Scholar
- cf5b2a15296e7832bcfdd965f28583772ef2999c
- Cited by
- 713
- References
- 215
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 33 · 2021: 46 · 2020: 26 · 2019: 19 · 2018: 33 · 2017: 42 · 2016: 22 · 2015: 49 · 2014: 48 · 2013: 62 · 2012: 59
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 59883, MH066629, R01MH059883, R01MH066629)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- modafinil, wakefulness-promoting agents, neurochemical mechanisms, cognition, catecholamines, serotonin, glutamate, GABA, orexin, histamine, working memory, episodic memory, prefrontal cortex, cognitive control, treatment-resistant depression, attention deficit hyperactivity disorder, schizophrenia, cognitive impairment, pharmacokinetics, abuse liability
- MeSH terms
- Modafinil, Animals, Mental Disorders, Benzhydryl Compounds, Brain Chemistry, Cognition, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.